Rainbow
Rainbow is an AI-native discovery laboratory that unites its in-house Caduceus AI engine with accredited wet labs to discover and validate biomarkers, drugs, and vaccines under one roof. The company serves pharma, biotech, and academic partners through co-development and validation partnerships, while also providing accredited diagnostic testing for clinics.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
- Artificial Intelligence
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
Traditional drug and biomarker discovery is fragmented, with AI-driven discovery groups often outsourcing experimental validation to external labs, causing delays and inefficiencies. This handoff between computational prediction and wet-lab verification slows down the translation of hypotheses into validated candidates, and many organizations lack access to both AI capabilities and accredited laboratory infrastructure in one place.
Solution
Rainbow Laboratories unites an in-house AI discovery engine, Caduceus, with accredited wet labs to provide end-to-end discovery and validation services. Caduceus generates and prioritizes cited hypotheses across targets, modalities, and biomarkers, compressing literature review, target identification, modality choice, and assay design into a single guided workflow. The company's scientists then validate the strongest candidates at the bench, ensuring hypotheses move from screen to assay without leaving the building. Rainbow Laboratories works alongside universities and pharma through fee-for-service to milestone-based partnerships, and also provides accredited diagnostic testing for clinics with reliable turnaround and clinician-friendly reporting.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking co-development and validation partnerships, academic researchers pursuing translational collaborations with shared IP, and clinics requiring accredited diagnostic testing services.
Features
- Caduceus AI engine that generates cited, prioritized hypotheses across targets, modalities, and biomarkers
- Integrated CQC-registered, ISO 15189-aligned wet labs with UKAS accreditation in progress
- End-to-end workflow covering discovery, assay design, and analytical and clinical validation
- Co-development partnerships with universities and pharma, from fee-for-service to milestone-based models, including shared IP and grant co-applications
- Accredited diagnostic testing services for clinics with clinician-friendly reporting
- Single guided workflow that compresses literature review, target identification, modality choice, and assay design